Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer.
Interval debulking surgery
Neoadjuvant chemotherapy
Ovarian cancer
Peritoneal washing cytology
Prognosis
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
13
10
2023
accepted:
13
08
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
24
8
2024
Statut:
epublish
Résumé
Interval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been identified as a prognostic factor, its comprehensive assessment during IDS remains unexplored. Therefore, we aimed to evaluate PWC efficacy during IDS, alongside other factors including residual disease and the modeled cancer antigen 125 (CA-125) ELIMination rate constant K (KELIM), by retrospectively reviewing the medical records of 25 patients with advanced ovarian cancer underwent neoadjuvant chemotherapy and IDS between January 2017 to June 2023. Twelve (48.0%) patients were PWC-positive, and the remainder were PWC-negative. PWC was performed at laparotomy during IDS, after which five (41.7%) PWC-positive and four (30.8%) PWC-negative patients received bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, for maintenance treatment. Four (33.3%) PWC-positive and 10 (76.9%) PWC-negative patients received poly adenosine diphosphate (ADP)-ribose polymerase inhibitors. In patients who received bevacizumab and poly ADP-ribose polymerase inhibitors, overall survival and progression-free survival did not significantly differ between those who were PWC-positive and PWC-negative (p = 0.27 and 0.20, respectively). Progression-free survival significantly differed between those with favorable and unfavorable CA-125 KELIM (p = 0.02). Multivariate analysis indicated that optimal surgery and favorable CA-125 KELIM were associated with better progression-free survival (p < 0.01 and 0.02, respectively), with only optimal surgery associated with better overall survival (p = 0.04). A positive PWC at IDS was not associated with survival in advanced ovarian cancer. Our findings indicate that although PWC status at IDS should be one of the factors determining survival in patients with advanced ovarian cancer, recent improvements in maintenance therapy may make the combination of CA-125 KELIM and PWC status a more useful prognostic factor in selecting treatment after IDS. Further studies are needed to validate these results, highlighting the potential importance of maintenance treatment after IDS and the need for further research to validate the clinical significance of a positive PWC.
Sections du résumé
BACKGROUND
BACKGROUND
Interval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been identified as a prognostic factor, its comprehensive assessment during IDS remains unexplored. Therefore, we aimed to evaluate PWC efficacy during IDS, alongside other factors including residual disease and the modeled cancer antigen 125 (CA-125) ELIMination rate constant K (KELIM), by retrospectively reviewing the medical records of 25 patients with advanced ovarian cancer underwent neoadjuvant chemotherapy and IDS between January 2017 to June 2023.
RESULTS
RESULTS
Twelve (48.0%) patients were PWC-positive, and the remainder were PWC-negative. PWC was performed at laparotomy during IDS, after which five (41.7%) PWC-positive and four (30.8%) PWC-negative patients received bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, for maintenance treatment. Four (33.3%) PWC-positive and 10 (76.9%) PWC-negative patients received poly adenosine diphosphate (ADP)-ribose polymerase inhibitors. In patients who received bevacizumab and poly ADP-ribose polymerase inhibitors, overall survival and progression-free survival did not significantly differ between those who were PWC-positive and PWC-negative (p = 0.27 and 0.20, respectively). Progression-free survival significantly differed between those with favorable and unfavorable CA-125 KELIM (p = 0.02). Multivariate analysis indicated that optimal surgery and favorable CA-125 KELIM were associated with better progression-free survival (p < 0.01 and 0.02, respectively), with only optimal surgery associated with better overall survival (p = 0.04).
CONCLUSIONS
CONCLUSIONS
A positive PWC at IDS was not associated with survival in advanced ovarian cancer. Our findings indicate that although PWC status at IDS should be one of the factors determining survival in patients with advanced ovarian cancer, recent improvements in maintenance therapy may make the combination of CA-125 KELIM and PWC status a more useful prognostic factor in selecting treatment after IDS. Further studies are needed to validate these results, highlighting the potential importance of maintenance treatment after IDS and the need for further research to validate the clinical significance of a positive PWC.
Identifiants
pubmed: 39182152
doi: 10.1186/s13048-024-01494-1
pii: 10.1186/s13048-024-01494-1
doi:
Substances chimiques
CA-125 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Informations de copyright
© 2024. The Author(s).
Références
Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137:108–21.
doi: 10.1097/AOG.0000000000004173
pubmed: 33278287
Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, et al. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? J Gynecol Oncol. 2019;30:e81.
doi: 10.3802/jgo.2019.30.e81
pubmed: 31328461
pmcid: 6658596
Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther. 2011;11:1053–67.
doi: 10.1586/era.11.24
pubmed: 21806329
Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92:2585–91.
doi: 10.1002/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#
pubmed: 11745193
Iura A, Takita M, Kawano A, Imai K, Konnai K, Onose R, et al. Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer. J Gynecol Oncol. 2018;29:e70.
doi: 10.3802/jgo.2018.29.e70
pubmed: 30022634
pmcid: 6078894
Nagasaka K, Kawana K, Tomio K, Tsuruga T, Mori-Uchino M, Miura S, et al. Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: a retrospective study. J Obstet Gynaecol Res. 2015;41:755–62.
doi: 10.1111/jog.12616
pubmed: 25421004
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022;164:254–64.
doi: 10.1016/j.ygyno.2021.12.016
pubmed: 34952708
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166:219–29.
doi: 10.1016/j.ygyno.2022.05.020
pubmed: 35690498
Lee A. Niraparib: a review in first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 2021;16:839–45.
doi: 10.1007/s11523-021-00841-2
pubmed: 34635996
pmcid: 8613118
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, et al. CA-125 ELIMination Rate Constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the Phase II CHIVA trial. Clin Cancer Res. 2020;26:4625–32.
doi: 10.1158/1078-0432.CCR-20-0054
pubmed: 32209570
Prat J, FIGO Committee on Gynecologic Oncology. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26:87–9.
Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34:3854–63.
doi: 10.1200/JCO.2016.68.1239
pubmed: 27601552
pmcid: 5477982
Kojima N, Yoshida H, Kuno I, Uehara T, Uno M, Ishikawa M, et al. Prognostic impact of intraoperative peritoneal cytologyin interval debulking surgery for pelvic high-grade serous carcinoma. Cancer Med. 2019;8:4598–604.
doi: 10.1002/cam4.2377
pubmed: 31243928
pmcid: 6712449
Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, et al. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. Eur J Gynaecol Oncol. 2023;44:17–25.
pubmed: 36874058
pmcid: 9980410
Mao CL, Seow KM, Chen KH. The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. Int J Mol Sci. 2022;23:6911.
doi: 10.3390/ijms23136911
pubmed: 35805914
pmcid: 9266930
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28.
doi: 10.1056/NEJMoa1911361
pubmed: 31851799
Nagao S, Tamura J, Shibutani T, Miwa M, Kato T, Shikama A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study. Int J Clin Oncol. 2023;28:804–15.
doi: 10.1007/s10147-023-02329-7
pubmed: 37140771
pmcid: 10232639